Search form

Latest News

Quidel Receives FDA Clearance for Its AmpliVue Trichomonas Assay: A Hand-Held Molecular Diagnostic Test for Trichomoniasis

SAN DIEGO, CA -- (Marketwired) -- --
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received clearance from the United States Food and Drug Administration (FDA) to market its AmpliVue Trichomonas Assay for the detection of nucleic acids isolated from clinician-collected vaginal swab specimens obtained from symptomatic or asymptomatic female patients. This molecular assay aids in the diagnosis of trichomoniasis, a sexually transmitted disease attributable to infection by the Trichomonas vaginalis parasite.

Read More »

Careers

Are you a determined, optimistic, team player? Quidel is looking for talented innovators who want to be part of revolutionizing medical diagnostics.

View Current Job Openings

Support

We appreciate your efforts to improve patient care, physician services, and laboratory efficiency. We know that you will appreciate the value that Quidel brings in delivering diagnostics that do not sacrifice accuracy or ease-of-use. Please explore this site for helpful resources and how you can contact us for further support.